Inclusion of Plasma Lipid Species Improves Classification of Individuals at Risk of Type 2 Diabetes

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Wong, Gerard ^a   Barlow, Christopher K ^a   Weir, Jacquelyn M ^a   Jowett, Jeremy B M ^a   Magliano, Dianna J ^a   Zimmet, Paul ^a   Shaw, Jonathan ^a   Meikle, Peter J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIET RESTRICTION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIPID BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CODING; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION PROCESS; WAIST CIRCUMFERENCE;

AGED; BLOOD GLUCOSE; BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; LIPIDS; MALE; MASS SCREENING; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 84885151542     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076577     Document Type: Article

References (31)

1. Zimmet P, Alberti KG, Shaw J, (2001) Global and societal implications of the diabetes epidemic. Nature 414: 782-787.
2. Shaw JE, Tanamas S. (Eds) (2012) Diabetes: the silent pandemic and its impact on Australia.: Baker IDI Heart and Diabetes Institute.
3. Shaw JE, Sicree RA, Zimmet PZ, (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87: 4-14.
4. Magliano DJ, Peeters A, Vos T, Sicree R, Shaw J, et al. (2009) Projecting the burden of diabetes in Australia-what is the size of the matter? Aust N Z J Public Health 33: 540-543.
5. Magliano DJ, Shaw JE, Shortreed SM, Nusselder WJ, Liew D, et al. (2008) Lifetime risk and projected population prevalence of diabetes. Diabetologia 51: 2179-2186.
6. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, et al. (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 1343-1350.
7. DeFronzo RA, Abdul-Ghani M, (2011) Type 2 diabetes can be prevented with early pharmacological intervention. Diabetes Care 34Suppl 2: S202-209.
8. Rizza S, Cardellini M, Martelli E, Porzio O, Pecchioli C, et al. (2010) Occult impaired glucose regulation in patients with atherosclerosis is associated to the number of affected vascular districts and inflammation. Atherosclerosis 212: 316-320.
9. Rizza S, Copetti M, Cardellini M, Porzio O, Luzi A, et al. (2012) Atherosclerosis severity but not undiagnosed diabetes predicts new cardiovascular events of subjects in secondary cardiovascular prevention. Atherosclerosis.
10. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T (2011) Risk models and scores for type 2 diabetes: systematic review. BMJ 343.
11. Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, et al. (2009) Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes 58: 337-343.
12. Boon J, Hoy AJ, Stark R, Brown RD, Meex RC, et al. (2013) Ceramides contained in LDL are elevated in type 2 diabetes and promote inflammation and skeletal muscle insulin resistance. Diabetes 62: 401-410.
13. Dunstan DW, Zimmet PZ, Welborn TA, Cameron AJ, Shaw J, et al. (2002) The Australian Diabetes, Obesity and Lifestyle Study (AusDiab)-methods and response rates. Diabetes Res Clin Pract 57: 119-129.
14. Barr ELM, Magliano DJ, Zimmet P, Polkinghorne KR, Armstrong T, et al. (2006) AusDiab 2005. The Australia Diabetes, Obesity and Lifestyle Study. Tracking the accelerating epidemic: its causes and outcomes.: International Diabetes Institute, Melbourne (Baker IDI).
15. Barber MN, Risis S, Yang C, Meikle PJ, Staples M, et al. (2012) Plasma lysophosphatidylcholine levels are reduced in obesity and type 2 diabetes. PLoS One 7: e41456.
16. Cefalu WT, (2009) Inflammation, insulin resistance, and type 2 diabetes: back to the future? Diabetes 58: 307-308.
17. Rhee EP, Cheng S, Larson MG, Walford GA, Lewis GD, et al. (2011) Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 121: 1402-1411.
18. Grapov D, Adams SH, Pedersen TL, Garvey WT, Newman JW, (2012) Type 2 diabetes associated changes in the plasma non-esterified fatty acids, oxylipins and endocannabinoids. PLoS One 7: e48852.
19. Meikle PJ, Wong G, Tsorotes D, Barlow CK, Weir JM, et al. (2011) Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol 31: 2723-2732.
20. Borg ML, Andrews ZB, Duh EJ, Zechner R, Meikle PJ, et al. (2011) Pigment epithelium-derived factor regulates lipid metabolism via adipose triglyceride lipase. Diabetes 60: 1458-1466.
21. Boslem E, MacIntosh G, Preston AM, Bartley C, Busch AK, et al. (2011) A lipidomic screen of palmitate-treated MIN6 beta-cells links sphingolipid metabolites with endoplasmic reticulum (ER) stress and impaired protein trafficking. Biochem J 435: 267-276.
22. Chang C, Lin C, (2011) LIBSVM: A library for support vector machines. ACM Trans Intell Syst Technol 2: 1-27.
23. Boser B, Guyon I, Vapnik V. A training algorithm for optimal margin classifiers; 1992; Pittsburgh, Pennsylvania, United States. ACM. 144-152.
24. Cortes C, Vapnik V, (1995) Support-Vector Networks. Mach Learn 20: 273-297.
25. Stahlman M, Pham HT, Adiels M, Mitchell TW, Blanksby SJ, et al. (2012) Clinical dyslipidaemia is associated with changes in the lipid composition and inflammatory properties of apolipoprotein-B-containing lipoproteins from women with type 2 diabetes. Diabetologia 55: 1156-1166.
26. Defronzo RA, (2009) Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58: 773-795.
27. Erion DM, Shulman GI, (2010) Diacylglycerol-mediated insulin resistance. Nat Med 16: 400-402.
28. Boden G, (2011) Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18: 139-143.
29. Ortega FB, Lee D-c, Katzmarzyk PT, Ruiz JR, Sui X, et al. (2012) The intriguing metabolically healthy but obese phenotype: cardiovascular prognosis and role of fitness. European Heart Journal.
30. Karelis AD Metabolically healthy but obese individuals. The Lancet 372: 1281-1283.
31. Stefan N, Kantartzis K, Machann J, Schick F, Thamer C, et al. (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168: 1609-1616.